论文部分内容阅读
目的观察瑞舒伐他汀对预防冠脉支架术后再狭窄的临床疗效,探讨其对血脂和炎症因子水平的影响。方法 106例急性冠脉综合征冠脉支架植入患者,随机分为治疗组(瑞舒伐他汀10mg/d+常规用药)和对照组(常规用药);疗程均为6个月。治疗结束后入选病例复行冠脉造影,比较两组支架植入术后再狭窄率的差别及两组TC、TG、LDL-C、HDL-C和CRP水平。结果治疗组冠脉支架再狭窄率明显低于对照组(P<0.01),且普通支架和洗脱支架亚组均有相似结果。术后6个月,治疗组血清TC、TG、LDL-C和CRP水平明显低于对照组(P<0.01或0.05),而HDL-C明显高于对照组(P<0.05);治疗组再发心绞痛明显少于对照组(P<0.05)。结论瑞舒伐他汀可有效预防冠状动脉支架术后再狭窄、调节血脂、抑制炎症,且不良反应低,可长期服用。
Objective To observe the clinical effect of rosuvastatin on the prevention of restenosis after coronary stent implantation and to investigate the effect of rosuvastatin on the levels of lipids and inflammatory cytokines. Methods A total of 106 patients with acute coronary syndrome (ACS) coronary stents were randomly divided into treatment group (rosuvastatin 10 mg / d plus conventional medicine) and control group (conventional medicine) for 6 months. The patients underwent repeat coronary angiography at the end of treatment. The difference of restenosis rate and the levels of TC, TG, LDL-C, HDL-C and CRP were compared between the two groups after stent implantation. Results The rate of coronary stent restenosis in the treatment group was significantly lower than that in the control group (P <0.01), and both the common stent group and the eluting stent group had similar results. After 6 months, the levels of serum TC, TG, LDL-C and CRP in the treatment group were significantly lower than those in the control group (P <0.01 or 0.05), while the levels of HDL-C in the treatment group were significantly higher than those in the control group Angina pectoris was significantly less than the control group (P <0.05). Conclusion Rosuvastatin can prevent restenosis after coronary stenting, regulate blood lipids, inhibit inflammation, and have low side effects and long-term use.